Denali Therapeutics Inc. DNLI Finance Lease, Right-of-Use Asset, after Accumulated Amortization

Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies

L3Harris TechnologiesLHX

$192M-5.0%

ON SemiconductorON

$0-100%

Duke EnergyDUK

$3M-57.1%

Xcel EnergyXEL

$1.43B—

T-Mobile USTMUS

$2.77B-7.1%

State StreetSTT

$182M+34.8%

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s finance lease, right-of-use asset, after accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s finance lease, right-of-use asset, after accumulated amortization?: Denali Therapeutics Inc. (DNLI) reported finance lease, right-of-use asset, after accumulated amortization of $47.62M in Q1 2026.
How has Denali Therapeutics Inc.'s finance lease, right-of-use asset, after accumulated amortization changed year-over-year?: Denali Therapeutics Inc.'s finance lease, right-of-use asset, after accumulated amortization decreased by 5.1% year-over-year, from $50.2M to $47.62M.